DUSA Pharmaceuticals Reports Third Quarter 2010 Corporate Highlights and Financial Results

WILMINGTON, Mass., Nov. 5, 2010 /PRNewswire/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the third quarter ended September 30, 2010.

Third quarter and year-to-date financial highlights:

• Domestic Kerastick® revenues totaled $6.7 million for the third quarter of 2010, representing a $0.9 million or 15% improvement as compared to the third quarter of 2009. Year-to-date 2010 domestic Kerastick® revenues totaled $21.8 million, representing a $4.7 million or 27% improvement year-over-year.
• The Company experienced significant bottom line improvement on a GAAP basis for both the third quarter of 2010 and on a year-to-date basis.
  • The Company reached break-even on a GAAP basis for the third quarter of 2010, representing a $0.4 million improvement year-over-year.
  • The Company’s GAAP net loss on a year-to-date basis for 2010 was ($0.2) million, representing a $2.7 million improvement year-over-year.
• The Company generated net income on a non-GAAP basis for both the third quarter of 2010 and on a year-to-date basis.
  • Non-GAAP net income for the third quarter of 2010 was $0.6 million, representing a $0.8 million improvement year-over-year.
  • Non-GAAP net income on a year-to-date basis for 2010 was $1.2 million, representing a $3.1 million year-over-year improvement.

Management Comments:

“We are pleased with the significant improvements we continue to achieve in our financial results,” stated Robert Doman, President and CEO. “Despite the typical seasonality that we experience in the third quarter of each year, and the absence of the positive impact that a price increase announcement had on our prior year quarterly volume, we were able to grow our domestic Kerastick® revenue and generate profitability during the third quarter of 2010.”

“In each of the last four reporting quarters, the Company has been cash flow positive and/or profitable, generating cumulative positive cash flow and non-GAAP profitability of $2.0 million and $2.1 million, respectively,” continued Doman.

“We have demonstrated our ability to achieve profitability and generate positive cash flow over a rolling twelve month period. As we exit the third quarter, we remain focused on achieving our goals of becoming both cash flow positive and profitable for the full calendar year 2010,” concluded Doman.

Third Quarter 2010 Financial Results:

Total product revenues were $8.0 million in the third quarter of 2010, an increase of $1.1 million or 16% from $6.9 million in the third quarter of 2009. PDT revenues totaled $7.8 million, an increase of $1.1 million or 17% from $6.7 million for the comparable 2009 period. The increase in PDT revenues was attributable to a $1.3 million increase in Kerastick® revenues which was partially offset by a $0.2 million decrease in BLU-U® revenues. The Kerastick® revenue improvement was driven by a 12% increase in our average selling price, as well as, the acceleration of the recognition of $0.6 million in deferred revenues and milestone payments associated with the termination of our Marketing, Distribution and Supply Agreement with Stiefel Laboratories, Inc. for Latin America. Kerastick® sales volumes increased slightly to 53,724 units sold in the third quarter of 2010 from 53,622 units sold in the comparable 2009 period. Domestic Kerastick® sales volumes increased by 2,742 units or 6% and were offset by a 2,640 unit decrease in our international sales volumes. BLU-U® revenues totaled $0.3 million, down $0.2 million year-over-year. There were 39 units sold during the third quarter, as compared to the 59 units sold in the comparable prior year quarter. Non-PDT revenues were relatively flat year-over-year at $0.2 million.

DUSA reached break-even on a GAAP basis for the third quarter of 2010, compared to a net loss of ($0.4) million or ($0.02) per common share in the third quarter of 2009.

Please refer to the section entitled “Use of Non-GAAP Financial Measures” and the accompanying financial table included at the end of this release for a reconciliation of GAAP to non-GAAP results for the three and nine-month periods ended September 30, 2010 and 2009, respectively.

DUSA’s non-GAAP net income for the third quarter of 2010 was $0.6 million or $0.02 per common share, compared to a net loss of ($0.2) million or ($0.01) per common share in the prior year period. The improvement in the Company’s profitability was the result of the year-over-year increase in our PDT revenues and the recognition of $0.5 million in income from operations related to the termination of the Stiefel Agreement, both of which were partially offset by an increase in our operating costs.

Year-to-Date 2010 Financial Results:

Total product revenues for the nine-month period ended September 30, 2010 were $25.4 million, an increase of $4.4 million or 21% from $21.0 million in the comparable prior year period. PDT revenues totaled $24.5 million, an increase of $4.7 million or 24% from $19.8 million for the comparable 2009 period. The increase in PDT revenues was attributable to a $5.1 million increase in Kerastick® revenues which was partially offset by a $0.4 million decrease in BLU-U® revenues. The Kerastick® revenue improvement was driven by a 14% increase in volume, a 9% increase in average selling price; as well as, the acceleration of the recognition of $0.6 million in deferred revenues and milestone payments associated with the termination of our Marketing, Distribution and Supply Agreement with Stiefel Laboratories, Inc. for Latin America. Kerastick® sales volumes increased to 176,924 units in 2010 from 155,384 units sold in 2009. Domestic Kerastick® sales volumes increased by 27,384 units or 19% and were partially offset by a 5,844 decrease in our international sales volumes. The BLU-U® revenue decline was as result of a both lower sales volumes and a lower average selling price. There were 179 units sold during the first nine months of 2010, as compared to the 198 units sold in the comparable prior year period. The average selling price in 2010 is reflective of lower pricing offered to customers in advance of the introduction of the upgraded BLU-U® design which became available in April 2010. Non-PDT revenues totaled $0.9 million down $0.3 million from the prior year period due to the absence of Nicomide® royalties from River’s Edge Pharmaceuticals, LLC.

DUSA’s net loss on a GAAP basis for the nine-month period ended September 30, 2010 was ($0.2) million or ($0.01) per common share, compared to a net loss of ($2.9) million or ($0.12) per common share in 2009.

DUSA’s non-GAAP net income for the nine-month period ended September 30, 2010 was $1.2 million or $0.05 per common share in 2010, compared to a net loss of ($1.9) million or ($0.08) per common share in 2009. The improvement in the Company’s non-GAAP profitability was the result of the year-over-year increase in our PDT revenues and the recognition of $0.5 million in income from operations related to the termination of the Stiefel Agreement, both of which were partially offset by an increase in our operating costs.

As of September 30, 2010, total cash, cash equivalents, and marketable securities were $17.0 million, compared to $16.7 million at December 31, 2009. The Company generated $0.3 million in positive cash flow during the first nine months of 2010.

Other Updates:

• On August 6, 2010, the Company reported that it had been notified by the U.S. Food and Drug Administration (FDA) that it had not been granted Orphan Drug Designation for the use of Levulan® (aminolevulinic acid HCl) Photodynamic Therapy (PDT) for the prevention of cutaneous squamous cell carcinomas (SCCs) in patients who have a proven history of multiple localized cutaneous SCCs over a 12 month period. The FDA acknowledged that cutaneous SCC is a serious problem in patients at high risk for developing SCCs, such as solid organ transplant recipients (SOTRs), and that aminolevulinic acid would be a potential preventative therapy in these patients. However, the FDA also stated that it believes there are other factors which place patients at high risk of developing SCCs that should be included in determining the target population which FDA determined would then exceed the maximum population permitted by orphan drug laws. As a result, the Company plans to close out its SOTR pilot clinical trial program for this indication.
• On September 30, 2010, the Company terminated its Marketing, Distribution and Supply Agreement with Stiefel Laboratories, Inc. for Latin America. The termination of the agreement accelerated the recognition of deferred revenues for drug shipments made; as well as, the remaining unamortized balance of milestone payments received. This event caused the recognition of $0.5 million in income from operations, which was recorded during the third quarter of 2010.
• On October 26, 2010, the Company announced that it had been named to Deloitte’s 2010 Technology Fast 500 list. For the third consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications, life sciences, and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the period 2005-2009.

Conference Call Details and Dial-in Information:

In conjunction with this announcement, DUSA will host a conference call today:

The call will be accessible on our web site approximately six hours following the call at www.dusapharma.com.

Revenues Table, Condensed Consolidated Balance Sheets, Condensed Consolidated Statement of Operations and GAAP to Non-GAAP reconciliation follow:

Revenues for the three and nine-month periods were comprised of the following: